{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:17:34Z","timestamp":1793146654217,"version":"4.5.0"},"reference-count":25,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2022,4,17]],"date-time":"2022-04-17T00:00:00Z","timestamp":1650153600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Rituximab, an anti\u2010CD20 monoclonal antibody, can be used to treat immune thrombotic thrombocytopenic purpura (iTTP) during acute presentation or disease relapse. Undesirable side\u2010effects include severe hypersensitivity reactions, particularly anaphylaxis and rituximab\u2010induced serum sickness, with a minority not maintaining a response to treatment. Alternative humanised anti\u2010CD20 treatments, obinutuzumab and ofatumumab, have been used. A review of the UK TTP Registry showed 15 patients received these drugs over 26 treatment episodes (eight obinutuzumab and 18 ofatumumab). Indications for alternative anti\u2010CD20 treatment were severe infusion\u2010related reactions, acute rituximab\u2010induced serum sickness and a short duration of disease remission. All patients achieved disease remission (ADAMTS13 [A disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13] activity \u226530\u2009iu\/dl) after a median 15\u2009days and 92% of episodes achieved complete remission (\u226560\u2009iu\/dl). Seven patients required further treatment for disease relapse with a median relapse\u2010free survival of 17.4\u2009months. All patients continued to respond to re\u2010treatment with the preceding drug when relapse occurred. There were four adverse events in 26 treatment episodes (15%) \u2013 two infections and two infusion reactions. These results suggest that obinutuzumab and ofatumumab may be considered as an alternative option to rituximab in the treatment of iTTP with a comparable safety profile, absence of significant hypersensitivity reactions and sustained normalisation of ADAMTS13.<\/jats:p>","DOI":"10.1111\/bjh.18192","type":"journal-article","created":{"date-parts":[[2022,4,17]],"date-time":"2022-04-17T23:24:28Z","timestamp":1650237868000},"page":"391-396","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["The use of obinutuzumab and ofatumumab in the treatment of immune thrombotic thrombocytopenic purpura"],"prefix":"10.1111","volume":"198","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1001-0486","authenticated-orcid":false,"given":"Andrew J.","family":"Doyle","sequence":"first","affiliation":[{"name":"Department of Haematology University College Hospitals London NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Stubbs","sequence":"additional","affiliation":[{"name":"Department of Haematology University College Hospitals London NHS Foundation Trust  London UK"},{"name":"Cardiometabolic Programme University College London Hospitals Biomedical Research Centre, National Institute for Health Research  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Will","family":"Lester","sequence":"additional","affiliation":[{"name":"Department of Haematology University Hospitals Birmingham  Birmingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8740-0194","authenticated-orcid":false,"given":"Will","family":"Thomas","sequence":"additional","affiliation":[{"name":"Department of Haematology Cambridge University Hospitals NHS Foundation Trust  Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John\u2010Paul","family":"Westwood","sequence":"additional","affiliation":[{"name":"Department of Haematology University College Hospitals London NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Thomas","sequence":"additional","affiliation":[{"name":"Department of Haematology University College Hospitals London NHS Foundation Trust  London UK"},{"name":"Cardiometabolic Programme University College London Hospitals Biomedical Research Centre, National Institute for Health Research  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Percy","sequence":"additional","affiliation":[{"name":"Department of Haematology University Hospitals Birmingham  Birmingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nithya","family":"Prasannan","sequence":"additional","affiliation":[{"name":"Department of Haematology University College Hospitals London NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Scully","sequence":"additional","affiliation":[{"name":"Department of Haematology University College Hospitals London NHS Foundation Trust  London UK"},{"name":"Cardiometabolic Programme University College London Hospitals Biomedical Research Centre, National Institute for Health Research  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,4,17]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102011\u201003\u2010341131"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24559"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102016\u201003\u2010703827"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12114"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009150"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017008268"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102014\u201001\u2010550244"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.572863"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2015.06.014"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2019.06.009"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15177"},{"key":"e_1_2_7_13_1","unstructured":"MabThera: EPAR \u2013 Product Information.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/mabthera\u2010epar\u2010product\u2010information_en.pdf(Accessed 30\/11\/2021)."},{"key":"e_1_2_7_14_1","unstructured":"Ofatumumab: SMPC.https:\/\/www.medicines.org.uk\/emc\/product\/12433\/smpc#grefObin(Accessed 30\/11\/2021)."},{"key":"e_1_2_7_15_1","unstructured":"Obinutuzumab: SMPC.https:\/\/www.medicines.org.uk\/emc\/product\/3279(Accessed 30\/11\/2021)."},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917246"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmc1714146"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11239\u2010018\u20101647\u20109"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25583"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1801263"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/bcr\u20102019\u2010232896"},{"issue":"12","key":"e_1_2_7_22_1","first-page":"1338","article-title":"Successful treatment of pemphigus vulgaris with ofatumumab","volume":"17","author":"Rapp M","year":"2018","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis\u20102021\u2010220920"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/0961203319881500"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614598"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2828"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.18192","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.18192","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.18192","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T22:58:50Z","timestamp":1692831530000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.18192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,17]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.1111\/bjh.18192"],"URL":"https:\/\/doi.org\/10.1111\/bjh.18192","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,17]]},"assertion":[{"value":"2022-02-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}